Sanofi’s lat­est R&D re­mod­el­ing spot­lights what’s hot (bis­pecifics) and what’s not (CT­LA-4) in on­col­o­gy to­day

Sanofi’s pipeline re­mod­el­ing pro­gram has claimed a piv­otal com­bo ap­proach to lung can­cer along with a score of oth­er ter­mi­na­tions in Q4. And the moves un­der­score what’s hot — and not — in the on­col­o­gy field.

Out­lin­ing the moves in their quar­ter­ly sit-down with an­a­lysts, Sanofi hit the kill switch on 13 de­vel­op­ment pro­grams and 25 re­search projects. But the R&D group al­so hit the gas on 17 pro­grams, about half of which are in on­col­o­gy.

New R&D chief John Reed is press­ing a strat­e­gy es­tab­lished by Elias Zer­houni, which in­volves more of an in-house fo­cus, par­tic­u­lar­ly in the wake of the re­cent Abl­ynx and Biover­a­tiv buy­outs, which added new re­search ca­pa­bil­i­ties and drugs to the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER